{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:57:51Z","timestamp":1779357471345,"version":"3.51.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03650-w","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:16:13Z","timestamp":1765962973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases"],"prefix":"10.1186","volume":"23","author":[{"given":"Aaron B.","family":"Kantor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Rickert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hank","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasudha","family":"Salgotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana","family":"Suppahia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Kyu","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"Widboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Warfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Akassoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Stavenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"3650_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.neuron.2013.10.008","volume":"80","author":"C Iadecola","year":"2013","unstructured":"Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844\u201366.","journal-title":"Neuron"},{"key":"3650_CR2","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1016\/j.cell.2024.09.018","volume":"187","author":"K Akassoglou","year":"2024","unstructured":"Akassoglou K, Davalos D, Mendiola AS, Petersen MA, Ryu JK, Schachtrup C, et al. Pioneering discovery and therapeutics at the brain-vascular-immune interface. Cell. 2024;187:5871\u20136.","journal-title":"Cell"},{"key":"3650_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrn.2018.13","volume":"19","author":"MA Petersen","year":"2018","unstructured":"Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19:283\u2013301.","journal-title":"Nat Rev Neurosci"},{"key":"3650_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.14283\/jpad.2023.105","volume":"10","author":"AB Kantor","year":"2023","unstructured":"Kantor AB, Akassoglou K, Stavenhagen JB. Fibrin-targeting immunotherapy for dementia. J Prev Alzheimers Dis. 2023;10:647\u201360.","journal-title":"J Prev Alzheimers Dis"},{"key":"3650_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03831-3","author":"A Farinas","year":"2025","unstructured":"Farinas A, Rutledge J, Bot VA, Western D, Ying K, Lawrence KA, et al. Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging. Nat Med. 2025;31:2578\u201389.","journal-title":"Nat Med"},{"key":"3650_CR6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/1352458519852723","volume":"25","author":"D Davalos","year":"2019","unstructured":"Davalos D, Mahajan KR, Trapp BD. Brain fibrinogen deposition plays a key role in MS pathophysiology - yes. Mult Scler. 2019;25:1434\u20135.","journal-title":"Mult Scler"},{"key":"3650_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.24997","volume":"82","author":"RL Yates","year":"2017","unstructured":"Yates RL, Esiri MM, Palace J, Jacobs B, Perera R, DeLuca GC. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann Neurol. 2017;82:259\u201370.","journal-title":"Ann Neurol"},{"key":"3650_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.nbd.2005.06.012","volume":"20","author":"CM Vos","year":"2005","unstructured":"Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bo L, van der Valk P, et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis. 2005;20:953\u201360.","journal-title":"Neurobiol Dis"},{"key":"3650_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13322","author":"R Magliozzi","year":"2024","unstructured":"Magliozzi R, Hametner S, Mastantuono M, Mensi A, Karimian M, Griffiths L, et al. Neuropathological and cerebrospinal fluid correlates of choroid plexus inflammation in progressive multiple sclerosis. Brain Pathol. 2025;35:e13322.","journal-title":"Brain Pathol"},{"key":"3650_CR10","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00125-007-0627-y","volume":"50","author":"M Garc\u00eda-Ram\u00edrez","year":"2007","unstructured":"Garc\u00eda-Ram\u00edrez M, Canals F, Hern\u00e1ndez C, Colom\u00e9 N, Ferrer C, Carrasco E, et al. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia. 2007;50:1294\u2013303.","journal-title":"Diabetologia"},{"key":"3650_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/dmrr.2419","volume":"29","author":"C Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez C, Garc\u00eda-Ram\u00edrez M, Colom\u00e9 N, Corraliza L, Garc\u00eda-Pascual L, Casado J, et al. Identification of new pathogenic candidates for diabetic macular edema using fluorescence-based difference gel electrophoresis analysis. Diabetes Metab Res Rev. 2013;29:499\u2013506.","journal-title":"Diabetes Metab Res Rev"},{"key":"3650_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096895","volume":"9","author":"MJ Koss","year":"2014","unstructured":"Koss MJ, Hoffmann J, Nguyen N, Pfister M, Mischak H, Mullen W, et al. Proteomics of vitreous humor of patients with exudative age-related macular degeneration. PLoS One. 2014;9:e96895.","journal-title":"PLoS One"},{"key":"3650_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00281-019-00750-7","volume":"41","author":"M Mesquida","year":"2019","unstructured":"Mesquida M, Drawnel F, Fauser S. The role of inflammation in diabetic eye disease. Semin Immunopathol. 2019;41:427\u201345.","journal-title":"Semin Immunopathol"},{"key":"3650_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00175927","volume":"230","author":"T Murata","year":"1992","unstructured":"Murata T, Ishibashi T, Inomata H. Immunohistochemical detection of extravasated fibrinogen (fibrin) in human diabetic retina. Graefes Arch Clin Exp Ophthalmol. 1992;230:428\u201331.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3650_CR15","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/s41467-023-37025-7","volume":"14","author":"M Kuchroo","year":"2023","unstructured":"Kuchroo M, DiStasio M, Song E, Calapkulu E, Zhang L, Ige M, et al. Single-cell analysis reveals inflammatory interactions driving macular degeneration. Nat Commun. 2023;14:2589.","journal-title":"Nat Commun"},{"key":"3650_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2018-07-818211","volume":"133","author":"JP Luyendyk","year":"2019","unstructured":"Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133:511\u201320.","journal-title":"Blood"},{"key":"3650_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","volume":"34","author":"D Davalos","year":"2012","unstructured":"Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34:43\u201362.","journal-title":"Semin Immunopathol"},{"key":"3650_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5450","volume":"374","author":"LM Silva","year":"2021","unstructured":"Silva LM, Doyle AD, Greenwell-Wild T, Dutzan N, Tran CL, Abusleme L, et al. Fibrin is a critical regulator of neutrophil effector function at the oral mucosal barrier. Science. 2021;374:eabl5450.","journal-title":"Science"},{"key":"3650_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41586-024-07873-4","volume":"633","author":"JK Ryu","year":"2024","unstructured":"Ryu JK, Yan Z, Montano M, Sozmen EG, Dixit K, Suryawanshi RK, et al. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024;633:905\u201313.","journal-title":"Nature"},{"issue":"1099\u20131108","key":"3650_CR20","volume":"101","author":"M Merlini","year":"2019","unstructured":"Merlini M, Rafalski VA, Rios Coronado PE, Gill TM, Ellisman M, Muthukumar G, et al. Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer\u2019s Disease Model. Neuron. 2019;101(1099\u20131108):e1096.","journal-title":"Neuron"},{"key":"3650_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41590-023-01522-0","volume":"24","author":"AS Mendiola","year":"2023","unstructured":"Mendiola AS, Yan Z, Dixit K, Johnson JR, Bouhaddou M, Meyer-Franke A, et al. Defining blood-induced microglia functions in neurodegeneration through multiomic profiling. Nat Immunol. 2023;24:1173\u201387.","journal-title":"Nat Immunol"},{"key":"3650_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9164","volume":"6","author":"JK Ryu","year":"2015","unstructured":"Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015;6:8164.","journal-title":"Nat Commun"},{"key":"3650_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12974-024-03092-w","volume":"21","author":"T Dean","year":"2024","unstructured":"Dean T, Mendiola AS, Yan Z, Meza-Acevedo R, Cabriga B, Akassoglou K, et al. Fibrin promotes oxidative stress and neuronal loss in traumatic brain injury via innate immune activation. J Neuroinflammation. 2024;21:94.","journal-title":"J Neuroinflammation"},{"key":"3650_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1084\/jem.20061931","volume":"204","author":"RA Adams","year":"2007","unstructured":"Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007;204:571\u201382.","journal-title":"J Exp Med"},{"key":"3650_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2230","volume":"3","author":"D Davalos","year":"2012","unstructured":"Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227.","journal-title":"Nat Commun"},{"key":"3650_CR26","first-page":"2428","volume":"35","author":"PY Paterson","year":"1976","unstructured":"Paterson PY. Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc. 1976;35:2428\u201334.","journal-title":"Fed Proc"},{"key":"3650_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.neuron.2010.05.014","volume":"66","author":"M Cortes-Canteli","year":"2010","unstructured":"Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer\u2019s disease. Neuron. 2010;66:695\u2013709.","journal-title":"Neuron"},{"key":"3650_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17590914221131446","volume":"14","author":"B Sarker","year":"2022","unstructured":"Sarker B, Cardona SM, Church KA, Vanegas D, Velazquez P, Rorex C, et al. Defibrinogenation ameliorates retinal microgliosis and inflammation in a CX3CR1-independent manner. ASN Neuro. 2022;14:1\u201318.","journal-title":"ASN Neuro"},{"key":"3650_CR29","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41590-023-01542-w","volume":"24","author":"Fibrin induces neurotoxic microglia gene programs in neurodegeneration","year":"2023","unstructured":"Fibrin induces neurotoxic microglia gene programs in neurodegeneration. Nat Immunol. 2023;24:1062\u20133.","journal-title":"Nat Immunol"},{"key":"3650_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114870","volume":"43","author":"SR Miller","year":"2024","unstructured":"Miller SR, Luxem K, Lauderdale K, Nambiar P, Honma PS, Ly KK, et al. Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer\u2019s disease models. Cell Rep. 2024;43:114870.","journal-title":"Cell Rep"},{"key":"3650_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2021-153148","volume":"138","author":"B Sharma","year":"2021","unstructured":"Sharma B, Kudira R, Rosenfeldt LA, Gourley BE, Cantrell R, Watanabe M, et al. Fibrin(ogen) promotes immune cell infiltration, dysbiosis and ROS production in experimental colitis. Blood. 2021;138:443.","journal-title":"Blood"},{"key":"3650_CR32","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1172\/JCI92744","volume":"127","author":"AK Kopec","year":"2017","unstructured":"Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest. 2017;127:3152\u201366.","journal-title":"J Clin Invest"},{"key":"3650_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41590-018-0232-x","volume":"19","author":"JK Ryu","year":"2018","unstructured":"Ryu JK, Rafalski VA, Meyer-Franke A, Adams RA, Poda SB, Rios Coronado PE, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol. 2018;19:1212\u201323.","journal-title":"Nat Immunol"},{"key":"3650_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/protein\/gzt047","volume":"26","author":"Y Xu","year":"2013","unstructured":"Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663\u201370.","journal-title":"Protein Eng Des Sel"},{"key":"3650_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mvr.2010.05.011","volume":"80","author":"HS Toma","year":"2010","unstructured":"Toma HS, Barnett JM, Penn JS, Kim SJ. Improved assessment of laser-induced choroidal neovascularization. Microvasc Res. 2010;80:295\u2013302.","journal-title":"Microvasc Res"},{"key":"3650_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.exer.2010.07.011","volume":"91","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91:537\u201343.","journal-title":"Exp Eye Res"},{"key":"3650_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/321522a0","volume":"321","author":"PT Jones","year":"1986","unstructured":"Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522\u20135.","journal-title":"Nature"},{"key":"3650_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-61779-974-7_13","volume":"907","author":"JH Kim","year":"2012","unstructured":"Kim JH, Hong HJ. Humanization by CDR grafting and specificity-determining residue grafting. Methods Mol Biol. 2012;907:237\u201345.","journal-title":"Methods Mol Biol"},{"key":"3650_CR39","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114:944\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3650_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.sbi.2007.08.012","volume":"17","author":"SA Gai","year":"2007","unstructured":"Gai SA, Wittrup KD. Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol. 2007;17:467\u201373.","journal-title":"Curr Opin Struct Biol"},{"key":"3650_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS One. 2021;16:e0260954.","journal-title":"PLoS One"},{"key":"3650_CR42","doi-asserted-by":"publisher","first-page":"2200540","DOI":"10.1080\/19420862.2023.2200540","volume":"15","author":"T Jain","year":"2023","unstructured":"Jain T, Boland T, V\u00e1squez M. Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches. MAbs. 2023;15:2200540.","journal-title":"MAbs"},{"key":"3650_CR43","doi-asserted-by":"publisher","first-page":"12942","DOI":"10.1021\/bi026324c","volume":"41","author":"VK Lishko","year":"2002","unstructured":"Lishko VK, Kudryk B, Yakubenko VP, Yee VC, Ugarova TP. Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry. 2002;41:12942\u201351.","journal-title":"Biochemistry"},{"key":"3650_CR44","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.3823878","volume":"235","author":"HM Geysen","year":"1987","unstructured":"Geysen HM, Tainer JA, Rodda SJ, Mason TJ, Alexander H, Getzoff ED, et al. Chemistry of antibody binding to a protein. Science. 1987;235:1184\u201390.","journal-title":"Science"},{"key":"3650_CR45","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1126\/science.2410982","volume":"229","author":"JA Berzofsky","year":"1985","unstructured":"Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure. Science. 1985;229:932\u201340.","journal-title":"Science"},{"key":"3650_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad392","author":"Y Myung","year":"2023","unstructured":"Myung Y, Pires DEV, Ascher DB. Understanding the complementarity and plasticity of antibody\u2013antigen interfaces. Bioinformatics. 2023;37:btad392.","journal-title":"Bioinformatics"},{"key":"3650_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.coi.2008.05.010","volume":"20","author":"AF Labrijn","year":"2008","unstructured":"Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol. 2008;20:479\u201385.","journal-title":"Curr Opin Immunol"},{"key":"3650_CR48","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","volume":"20","author":"LG Presta","year":"2008","unstructured":"Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008;20:460\u201370.","journal-title":"Curr Opin Immunol"},{"key":"3650_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126442","author":"A Kouhi","year":"2021","unstructured":"Kouhi A, Pachipulusu V, Kapenstein T, Hu P, Epstein AL, Khawli LA. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int J Mol Sci. 2021;22:6442.","journal-title":"Int J Mol Sci"},{"key":"3650_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5:297\u2013305.","journal-title":"MAbs"},{"key":"3650_CR51","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/brain\/awy082","volume":"141","author":"NJ Lee","year":"2018","unstructured":"Lee NJ, Ha SK, Sati P, Absinta M, Luciano NJ, Lefeuvre JA, et al. Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain. 2018;141:1637\u201349.","journal-title":"Brain"},{"key":"3650_CR52","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.3389\/fimmu.2019.02437","volume":"10","author":"MA Migotto","year":"2019","unstructured":"Migotto MA, Mardon K, Orian J, Weckbecker G, Kneuer R, Bhalla R, et al. Efficient distribution of a novel Zirconium-89 labeled anti-CD20 antibody following subcutaneous and intravenous administration in control and experimental autoimmune encephalomyelitis-variant mice. Front Immunol. 2019;10:2437.","journal-title":"Front Immunol"},{"key":"3650_CR53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","volume":"29","author":"HE Grossniklaus","year":"2010","unstructured":"Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29:500\u201319.","journal-title":"Prog Retin Eye Res"},{"key":"3650_CR54","doi-asserted-by":"crossref","unstructured":"Zhao M, Xie W, Hein TW, Kuo L, Rosa RH: Laser-Induced Choroidal Neovascularization in Rats. In Cardiovascular Development: Methods and Protocols. Edited by Peng X, Zimmer WE. New York, NY: Springer US; 2021: 77\u201385","DOI":"10.1007\/978-1-0716-1480-8_9"},{"key":"3650_CR55","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591\u2013604.","journal-title":"J Biol Chem"},{"key":"3650_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs. 2024;38:5\u201322.","journal-title":"BioDrugs"},{"key":"3650_CR57","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"3650_CR58","doi-asserted-by":"crossref","unstructured":"Bathini J, Schilling S, Lemere CA. Anti-Amyloid Immunotherapy for AD: a potential link between ARIA and complement. Alzheimers Dement. 2024;20:e093183.","DOI":"10.1002\/alz.093183"},{"key":"3650_CR59","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1177\/13524585241266483","volume":"30","author":"BF Bebo Jr","year":"2024","unstructured":"Bebo BF Jr, Banwell BL, Whitacre CC, Coetzee T, Dalgas U, De Jager PL, et al. The refined pathways to cures research roadmap for multiple sclerosis cures. Mult Scler. 2024;30:1242\u201351.","journal-title":"Mult Scler"},{"key":"3650_CR60","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","volume":"8","author":"H Lassmann","year":"2012","unstructured":"Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8:647\u201356.","journal-title":"Nat Rev Neurol"},{"key":"3650_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051049","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021.","journal-title":"Cells"},{"key":"3650_CR62","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41433-022-02153-9","volume":"36","author":"U Chakravarthy","year":"2022","unstructured":"Chakravarthy U, Armendariz BG, Fauser S. 15 years of anti-VEGF treatment for nAMD: success or failure or something in between? Eye. 2022;36:2232\u20133.","journal-title":"Eye"},{"key":"3650_CR63","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","volume":"121","author":"E Daniel","year":"2014","unstructured":"Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656\u201366.","journal-title":"Ophthalmology"},{"key":"3650_CR64","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"3650_CR65","unstructured":"Horan T, Salim S. Characteristics and Management of Steroid-Induced Glaucoma. Eyenet Magazine. 2021:51\u20133."},{"key":"3650_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00109-024-02437-5","volume":"102","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhou A. Macrophage activation contributes to diabetic retinopathy. J Mol Med. 2024;102:585\u201397.","journal-title":"J Mol Med"},{"key":"3650_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.preteyeres.2018.10.003","volume":"69","author":"M Chen","year":"2019","unstructured":"Chen M, Luo C, Zhao J, Devarajan G, Xu H. Immune regulation in the aging retina. Prog Retin Eye Res. 2019;69:159\u201372.","journal-title":"Prog Retin Eye Res"},{"key":"3650_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010110","author":"C Altmann","year":"2018","unstructured":"Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018;19:110.","journal-title":"Int J Mol Sci"},{"key":"3650_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.10.2","volume":"62","author":"JX Ong","year":"2021","unstructured":"Ong JX, Nesper PL, Fawzi AA, Wang JM, Lavine JA. Macrophage-like cell density is increased in proliferative diabetic retinopathy characterized by optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2021;62:2.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3650_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12974-022-02562-3","volume":"19","author":"A Rajesh","year":"2022","unstructured":"Rajesh A, Droho S, Lavine JA. Macrophages in close proximity to the vitreoretinal interface are potential biomarkers of inflammation during retinal vascular disease. J Neuroinflammation. 2022;19:203.","journal-title":"J Neuroinflammation"},{"key":"3650_CR71","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1158\/1078-0432.CCR-17-0647","volume":"23","author":"HJ Dalton","year":"2017","unstructured":"Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clin Cancer Res. 2017;23:7034\u201346.","journal-title":"Clin Cancer Res"},{"key":"3650_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCRESAHA.120.316851","volume":"127","author":"G Eelen","year":"2020","unstructured":"Eelen G, Treps L, Li X, Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ Res. 2020;127:310\u201329.","journal-title":"Circ Res"},{"key":"3650_CR73","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1167\/iovs.17-22345","volume":"58","author":"Q Wei","year":"2017","unstructured":"Wei Q, Zhang T, Jiang R, Chang Q, Zhang Y, Huang X, et al. Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2017;58:5783\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3650_CR74","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI20741","volume":"113","author":"MJ Flick","year":"2004","unstructured":"Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2\/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113:1596\u2013606.","journal-title":"J Clin Invest"},{"key":"3650_CR75","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood-2012-09-453894","volume":"121","author":"MJ Flick","year":"2013","unstructured":"Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, et al. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood. 2013;121:1783\u201394.","journal-title":"Blood"},{"key":"3650_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100793","volume":"48","author":"A Casini","year":"2021","unstructured":"Casini A, Neerman-Arbez M, de Moerloose P. Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management. Blood Rev. 2021;48:100793.","journal-title":"Blood Rev"},{"key":"3650_CR77","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1083\/jcb.200801146","volume":"182","author":"TA Springer","year":"2008","unstructured":"Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol. 2008;182:791\u2013800.","journal-title":"J Cell Biol"},{"key":"3650_CR78","doi-asserted-by":"publisher","first-page":"9095","DOI":"10.1038\/s41467-024-53217-1","volume":"15","author":"S Nath","year":"2024","unstructured":"Nath S, Mart\u00ednez Santamar\u00eda JC, Chu Y-H, Choi JS, Conforti P, Lin J-D, et al. Interaction between subventricular zone microglia and neural stem cells impacts the neurogenic response in a mouse model of cortical ischemic stroke. Nat Commun. 2024;15:9095.","journal-title":"Nat Commun"},{"key":"3650_CR79","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41467-020-14466-y","volume":"11","author":"L Pous","year":"2020","unstructured":"Pous L, Deshpande SS, Nath S, Mezey S, Malik SC, Schildge S, et al. Fibrinogen induces neural stem cell differentiation into astrocytes in the subventricular zone via BMP signaling. Nat Commun. 2020;11:630.","journal-title":"Nat Commun"},{"key":"3650_CR80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.neuron.2017.10.008","volume":"96","author":"MA Petersen","year":"2017","unstructured":"Petersen MA, Ryu JK, Chang KJ, Etxeberria A, Bardehle S, Mendiola AS, et al. Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage. Neuron. 2017;96:1003-1012.e1007.","journal-title":"Neuron"},{"key":"3650_CR81","doi-asserted-by":"crossref","unstructured":"Kantor AB, Hoffman TAM, Mannick D, Lisman T, Huget J, Offman E, Shcindler R, Navia B: Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of THN391, a monoclonal antibody targeting the fibrin inflammatory epitope: Phase 1a clinical trial results. In AAIC 2025, Toronto: Canada In Press; 2025","DOI":"10.1002\/alz70859_101350"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03650-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03650-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:01:45Z","timestamp":1768824105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03650-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03650-w","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B.K., M.R., H.C., K.F., V.S., A.S., and J.S. are\/were employees of Therini Bio and have stock options and\/or stock in the company. P.F.W. and J.R.W. are employees of Adimab. K.A. is the scientific founder of Therini Bio. J.K.R., and K.A. are advisors and shareholders of Therini Bio, Inc. J.K.R., and K.A. contributions to this publication was as paid consultants for Therini Bio and partially by Therini Bio sponsored research to K.A. at the Gladstone Institutes. Views expressed here are their own and not those of The J. David Gladstone Institutes. K.A. has served as a consultant for F. Hoffmann-La Roche, Sanofi, and the Foundation for a Better World unrelated to this study. Their interests are managed by Gladstone Institutes in accordance with its conflict-of-interest policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}